The mammogram you’ve already had can tell you more. Clairity Breast™ reads it to estimate your risk over the next five years. Now available through Everlywell, with your results reviewed by a licensed provider and next steps drawn from national guidelines.
“For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk. By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere.”
Dr. Connie Lehman
Clairity Breast, the first FDA-authorized AI-driven software to estimate a woman’s five-year breast cancer risk from a screening mammogram, is now available directly to consumers through Everlywell. Women with a qualifying screening mammogram from the past 12 months can request the assessment without new imaging.
Connie Lehman, founder and CEO of Clairity, shares how AI-driven insights can improve early detection, personalize screening, and ultimately change the future of breast-cancer care.
In this episode of the SBI podcast, host Dr. Karla Sepulveda welcomes Connie Lehman, MD, PhD to discuss how artificial intelligence is transforming breast cancer risk assessment. Dr. Lehman explains how AI-powered analysis of mammograms can identify women at elevated risk who may be missed by traditional risk models, paving the way for more personalized screening strategies. She also shares the story behind the development of the Mirai model and Clarity Breast, discusses recent NCCN guideline updates incorporating AI-based risk assessment, and explores the potential impact on screening recommendations, equity, and patient care.
